# Lamotrigine Phase III Study in Bipolar I Disorder

> **NCT01602510** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 265 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Lamotrigine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01602510
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2017-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602510, "Lamotrigine Phase III Study in Bipolar I Disorder". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01602510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*